Drug Developer Must Face Suboxone Product-Hopping Claims

By Nicole Narea ( October 30, 2017, 9:25 PM EDT) -- A Pennsylvania federal judge found that sufficient evidence supports allegations that drug delivery developer MonoSol Rx LLC engaged in an anti-competitive scheme to delay generic versions of an opioid addiction treatment, rejecting the company's bid to toss the suit brought by more than 40 states Monday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!